Dermata Therapeutics (DRMA) and Revance Therapeutics (RVNC) said Tuesday they signed a collaboration agreement for a clinical study that will evaluate the use of Dermata's xyngari with Revance's daxxify for the treatment of primary axillary hyperhidrosis, which is a chronic condition that causes excessive armpit sweating.
The randomized 16-week phase 2a trial trial will compare xyngari with daxxify versus xyngari with placebo, tracking reductions in sweat production and other efficacy measures, the companies said.
Dermata previously demonstrated positive safety and efficacy results when pairing xyngari with a botulinum toxin in early clinical trials, they added.
Xyngari is a topical Spongilla powder that creates microchannels in the skin, supporting a needle-free method to deliver botulinum toxin, according to the companies.
Price: 3.65, Change: -0.04, Percent Change: -0.95
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。